What’s New in HER2-Positive Breast Cancer Treatments for 2025?

Overview of HER2 Breast Cancer

Approximately 20% of breast cancers are characterized by being HER2-positive, which necessitates specialized treatment strategies. The HER2 protein facilitates the growth of cancer cells, and treatments are developed to specifically target this protein. All breast cancer cases are initially assessed for HER2 status through biopsies, guiding the subsequent therapeutic approach.

HER2-Positive Breast Cancer Treatments

Monoclonal Antibodies

Monoclonal antibodies, such as trastuzumab (Herceptin), have transformed the treatment of HER2-positive breast cancer. As the pioneering targeted therapy of its kind, trastuzumab, when used with chemotherapy, has been associated with improved survival rates and a reduced risk of recurrence. These treatments function by attaching to HER2 receptors on cancer cells, blocking growth signals and assisting the immune system in eliminating these cells.

Combination Therapies

The combination of HER2-targeted therapies with chemotherapy is a standard approach for early-stage breast cancer, intending to enhance treatment effectiveness by maximizing the destruction of cancer cells. However, increased side effects may accompany the addition of chemotherapy, which healthcare professionals manage through dose adjustments and symptom control.

Advanced HER2-Specific Medications

1. Ado-trastuzumab emtansine (Kadcyla, T-DM1): Commonly used post-surgery for those with residual disease, this treatment is part of strategies to reduce the likelihood of recurrence. Administered every three weeks, it merges targeted antibody therapy with chemotherapy to deliver drugs directly to cancer cells.

2. Pertuzumab (Perjeta): Often added to trastuzumab and chemotherapy for high-risk recurrence cases, pertuzumab assists as a component of adjuvant or neoadjuvant treatment protocols, administered every three weeks for up to a year.

3. Neratinib (Nerlynx): An oral kinase inhibitor applied post-trastuzumab to further decrease recurrence risk. Administered daily for a year, it requires diligent monitoring for side effects like diarrhea and liver function issues.

Treatment for HER2-Positive Metastatic Breast Cancer

While monoclonal antibody therapies and kinase inhibitors are crucial in early-stage treatments, metastatic cases demand more comprehensive strategies. The combination of trastuzumab and pertuzumab is established as a central approach due to its effectiveness in managing disease progression. Clinical trials continue to explore the benefits of immunotherapy in HER2 metastatic breast cancer, with ongoing evaluations necessary for broader applications.

Hormonal Therapy for HR Positive Breast Cancer

For hormone receptor (HR) positive HER2 breast cancer cases, hormonal therapies are essential. Treatments often involve medications such as tamoxifen or aromatase inhibitors, designed to block hormone effects or reduce hormone levels to hinder cancer growth.

Emerging and Future Treatments

Consistent research and clinical trials are key to developing new treatments. In 2025, patients are encouraged to participate in clinical trials when appropriate, gaining access to new therapies and contributing to establishing new care standards.

Financial Considerations

HER2-targeted therapies are recognized for their costs, with trastuzumab potentially costing over $70,000 annually without insurance. Oral medications like neratinib may lead to additional costs based on prescription plan coverage. Financial assistance programs, including the Komen Financial Assistance Program, are available to help manage these expenses, alongside insurance options and prescription drug benefit plans.

Heart Health Monitoring

Heart health monitoring is critical during treatments like trastuzumab and ado-trastuzumab emtansine, which can result in heart issues, including congestive heart failure. Regular cardiovascular evaluations are recommended before and during treatment to identify and manage potential risks. Additionally, lifestyle modifications like healthy eating and regular physical activity can support cardiac health.

In 2025, HER2-positive breast cancer treatments in the US have evolved considerably, offering improvements in patient survival and quality of life. Understanding available treatment options, including targeted therapies and combination approaches, is vital for both patients and healthcare providers in developing optimal treatment plans. With continuing advances in research, the prospect of even more effective and personalized therapies offers hope for those affected by this aggressive form of breast cancer.

Sources:

• Mayo Clinic on HER2-positive Breast Cancer Treatments
• Komen on Trastuzumab and HER2-Targeted Therapies
• WebMD on Early-Stage HER2-Positive Breast Cancer Treatments

Disclaimer: All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. The information and materials contained in these pages and the terms, conditions and descriptions that appear, are subject to change without notice.